Actimmune Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Actimmune market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to increased healthcare investments, a greater focus on disease management and prevention, a rise in the prevalence of chronic and rare diseases, and the expansion of specialty pharmacies.

The projected growth in the forecast period is driven by an increase in drug approvals, more clinical trials, rising biotech innovations, a higher prevalence of rare diseases, and growing orphan drug incentives. Key trends in this period include technological advancements, innovative drug delivery systems, progress in biotechnology, and the integration of artificial intelligence (AI) in healthcare.

The increasing occurrence of infectious diseases is expected to drive growth in the actimmune market in the coming years. Infectious diseases are caused by harmful microorganisms, such as bacteria, viruses, fungi, or parasites, that invade the body. These diseases can spread through direct contact, contaminated surfaces, or vectors, and their severity varies depending on the pathogen and the immune response. Factors such as population growth, poor sanitation, climate change, and the spread of new pathogens contribute to the rising incidence of infectious diseases. Actimmune plays a role in fighting these diseases by enhancing the immune system's ability to detect and eliminate pathogens, including specific bacteria and viruses. It boosts immune responses by activating macrophages and other immune cells, making it essential in managing infections and reducing complications associated with immune deficiencies or chronic infections. For example, the UK Health Security Agency reported in February 2024 that tuberculosis (TB) cases in England increased by 10.7% in 2023, from 4,380 in 2022 to 4,850. Thus, the growing incidence of infectious diseases is driving the actimmune market forward.

The growing prevalence of chronic diseases is also expected to contribute to the growth of the actimmune market in the future. Chronic diseases are long-term conditions that last for a year or more, requiring ongoing medical care or limiting daily activities. The increasing prevalence of these diseases can be attributed to factors such as aging, unhealthy lifestyles, environmental factors, genetics, and improved diagnosis. Actimmune assists in managing chronic diseases by modulating the immune response and reducing inflammation. It is particularly effective in treating conditions such as chronic granulomatous disease and severe malignant osteopetrosis by enhancing immune function and slowing disease progression. For instance, Allergy UK, a national charity in the UK, reported in April 2024 that over 21 million people in the UK were affected by allergies, making them the most common chronic health condition reported in 2022. Projections suggest that by 2026, half of Europe's population will have at least one allergy. Therefore, the increasing prevalence of chronic diseases is further driving the growth of the actimmune market.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition enables Amgen to expand its oncology and cardiovascular treatment portfolio while boosting its biotechnology and drug development capabilities for future growth. Horizon Therapeutics, an Ireland-based biopharmaceutical company, is known for its focus on actimmune, a treatment for rare diseases such as chronic granulomatous disease (CGD) and osteopetrosis.

The key company operating in the actimmune market is Amgen Inc.

North America was the largest region in the actimmune market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actimmune report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the actimmune market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Actimmune is the brand name for interferon gamma-1b, a synthetic version of a naturally occurring protein that helps regulate the immune system. It is used to treat chronic granulomatous disease (CGD) and severe, malignant osteopetrosis by enhancing the immune system’s ability to fight infections and improve bone strength.

The primary indications for actimmune include chronic granulomatous disease (CGD), severe malignant osteopetrosis, and other conditions. CGD is a rare, inherited immunodeficiency disorder where certain white blood cells cannot effectively kill specific bacteria and fungi, resulting in recurrent infections and granuloma formation. Actimmune is used for pediatric, adult, and other patient groups. It is distributed through various channels, including hospital pharmacies, specialty pharmacies, and online pharmacies, ensuring wide accessibility.

The actimmune market research report is one of a series of new reports that provides actimmune market statistics, including actimmune industry global market size, regional shares, competitors with an actimmune market share, detailed actimmune market segments, market trends and opportunities, and any further data you may need to thrive in the actimmune industry. This actimmune market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actimmune market consists of sales of products such as subcutaneous injections and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.